Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q1 2025 Earnings Presentation
16 slides from Orion Oyj Class A's earnings presentation, Apr 23, 2025
Slide 1: Orion Interim Report January-March 2025
Orion Interim Report January-March 2025 23 April 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q1 2025 Highlights
Q1 2025 Highlights • Solid growth in four out of five business divisions • Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 • Phase III trial with levosimendan by Tenax Therapeutics, Inc. added to Orion’s Key clinical development pipeline 3 23 April 2025 © Orion Corporation
Slide 4: Q1 2025 Financial highlights
Q1 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 22.0% (18.2%) +14.9% +39.1% -29.7% 354.6 77.9 0.78 308.5 56.0 0.55 Q1/2024 Q1/2025 Q1/2024 Q1/2025 Q1/2024 Q1/2025 4 23 April 2025 © Orion Corporation
Slide 5: Net sales bridge (MEUR)
Net sales bridge (MEUR) 3.3 -5.1 6.8 -0.4 354.6 1.0 308.5 40.4 Q1/2024 1 2 3 4 5 6 Q1/2025 1 Innovative Medicines 4 Animal Health 2 Branded Products 5 Fermion 3 Generics and Consumer Health 6 Translation differences and Other operations 5 23 April 2025 © Orion Corporation The figures in the chart ar
Slide 6: Operating profit bridge (MEUR)
Operating profit bridge (MEUR) -1.1 0.3 -9.7 77.9 21.8 -5.6 2.5 13.7 56.0 Q1/2024 1 2 3 4 5 6 7 Q1/2025 1 Change in sales volume 5 Milestones 2 Changes in prices, cost and product mix 6 Other operating income and expenses 3 Exchange rate effect on gross margin 7 Fixed cost 4 Royalties 6 23 April 202
Slide 7: Innovative Medicines
Innovative Medicines +70.4% Nubeqa® sales (MEUR) 97.8 152 6.3 • Both Nubeqa® royalties and 36 product sales showed very strong growth 95 92 57.4 7.9 72 26 91.5 62 38 50 21 116 45 22 37 18 49.5 16 69 11 MEUR 51 54 41 32 29 27 Q1/2024 Q1/2025 2023 2023 2023 2024 2024 2024 2024 2025 Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 8: Branded Products
Branded Products +9.7% 77.0 Sales split • Easyhaler® product portfolio 70.2 7.2 (+8.1%) continued strong growth 5.5 9% with budesonide-formoterol combination product (+14.9%) as 23.4 22.1 a driver • CNS sales grew by 5.7% mainly 30% due to entacapone sales in Japan 60% 42.6 46.5 MEUR Q1/2024 Q1/2025
Slide 9: Generics and Consumer Health
Generics and Consumer Health +0.7% Sales split by geographic areas • Good availability of Orion 130.7 131.7 products in Scandinavia supported growth 11% 33.8 33.3 10% MEUR 20% 60% 96.8 98.4 Q1/2024 Q1/2025 Generic prescription drugs Finland and Baltics Eastern Europe Self-care products Scandinavia R
Slide 10: Animal Health and Fermion
Animal Health and Fermion Animal Health Fermion • Nice growth for Animal Health even with strong comparison +10.4% period 35.2 • Sales of the animal sedatives 31.9 8.8 product group decreased from 10.3 the comparison period, but were at a good level -27.3% 18.5 • Fermion’s capacity allocated more 26
Slide 11: TOP 10 products and total sales split by division
TOP 10 products and total sales split by division EUR vs. Product or product portfolio million Q1/2024 1. Nubeqa® 91.5 +84.9% 4% 10% 2. Easyhaler® product portfolio 45.1 +8.1% 28% 3. Entacapone products1 21.2 +6.0% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 8.8 -14.1% 5. Divina® series 7.2 +30
Slide 12: Key clinical development pipeline
Key clinical development pipeline Partner Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide Prostate cancer (mHSPC) ARASTEP / darolutamide Prostate cancer (BCR) OMAHA1 / opevesostat Prostate cancer (mCRPC) OMAHA2a / opevesostat Prostate cancer (mCRPC) CYPIDES
Slide 13: Some sustainability highlights from 2024
Some sustainability highlights from 2024 • Orion’s first CSRD report was published in March as part of the Report by the Board of Directors • More highlights from 2024 at: https://www.orionpharma.com/investors/orion-highlights-2024/ 13 23 April 2025 © Orion Corporation
Slide 14: Outlook for 2025
Outlook for 2025 Net sales EUR 1,550–1,650 million Operating profit EUR 350–450 million 14 23 April 2025 © Orion Corporation
Slide 15: Capital Markets Day in Helsinki on 22 May 2025
Capital Markets Day in Helsinki on 22 May 2025 15 23 April 2025 © Orion Corporation
Slide 16: Upcoming events
Upcoming events Capital Markets Day 22/5/2025 Half-Year Financial Report 1–6/2025 18/7/2025 Interim Report 1–9/2025 28/10/2025 16 23 April 2025 © Orion Corporation